Semaglutide for the Reduction of Arrhythmia Burden in Overweight AF Patients
Status:
Not yet recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this pilot study is to assess the feasibility of a double-blind, randomized
placebo-controlled trial of semaglutide 2.4 mg subcutaneously once weekly on top of standard
care compared to standard care alone.
Phase:
Phase 3
Details
Lead Sponsor:
Axel Brandes
Collaborators:
Herlev and Gentofte Hospital Hillerod Hospital, Denmark Hospital of South West Jutland Svendborg Hospital